On pharmaceutical risk minimization

Drug Safety

Volumn 31, Issue 9, 2008, Pages 737-742

  Callréus, Torbjörn ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

Legislation; Pharmaceutical risk management; Pharmacovigilance

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BENZODIAZEPINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLARITHROMYCIN; COLONY STIMULATING FACTOR; COTRIMOXAZOLE; CYCLOSPORIN; CYTOCHROME P450 3A4; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GANCICLOVIR; GLUCOCORTICOID; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; MERCAPTOPURINE; NATALIZUMAB; SEROTONIN 3 ANTAGONIST; SULFAMETHOXAZOLE; SULFONAMIDE; THIOPURINE METHYLTRANSFERASE;

BLOOD TOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL DECISION MAKING; CONTROL SYSTEM; CYTOMEGALOVIRUS INFECTION; DISEASE PREDISPOSITION; DRUG HYPERSENSITIVITY; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; EVIDENCE BASED PRACTICE; FLU LIKE SYNDROME; GENETIC POLYMORPHISM; HUMAN; NAUSEA AND VOMITING; NEUTROPENIA; NOTE; PATIENT CARE; PATIENT IDENTIFICATION; PATIENT INFORMATION; PATIENT MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; RISK COMMUNICATION; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SIDE EFFECT; TECHNIQUE; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COMMUNICATION; HUMANS; INFORMATION DISSEMINATION; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; RISK MANAGEMENT;

EID: 49749106001     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831090-00002     Document Type: Note

References (27)

1. Guidance for industry: premarketing risk assessment, March 2005 [online]. Available from URL: http://www.fda.gov/cder/guidance/6357fnl.htm [Accessed 2008 Jan 20]
2. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment, March 2005 [online]. Available from URL: http://www.fda.gov/cder/guidance/6359OCC.htm [Accessed 2008 Jan 20]
3. Guidance for industry: development and use of risk minimization action plans, March 2005 [online]. Available from URL: http://www.fda.gov/cder/ guidance/6358fnl.htm [Accessed 2008 Jan 20]
4. Guideline on risk management systems for medicinal products for human use, 14 November 2005 [online]. Available from URL: http://www.emea.europa.eu/ pdfs/human/euleg/9626805en.pdf [Accessed 2008 Jan 20]
5. Innovative drug development approaches (EMEA/127318/ 2007): final report of the EMEA/CHMP think-tank on innovative drug development, 22 March 2007 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/itf/ 12731807en.pdf [Accessed 2008 Jan 20]
6. The importance of pharmacovigilance: safety monitoring of medicinal products, 2002 [online]. Available from URL: http://www.who.int/medicinedocs/ collect/medicinedocs/pdf/s4893e/s4893e.pdf [Accessed 2008 Jan 20]
7. ICH harmonised tripartite guideline: pharmacovigilance planning (E2E), 18 November 2004 [online]. Available from URL: http://www.ich.org/LOB/media/ MEDIA1195.pdf [Accessed 2008 Jan 20]
8. Waller P. Risk management planning: time to deliver. Pharmacoepidemiol Drug Saf 2006; 15 (12): 850-1
9. Aronson JK. Adverse drug reactions: no farewell to harms. Br J Clin Pharmacol 2007 Feb; 63 (2): 131-5
10. Atuah KN, Hughes D, Pirmohamed M. Clinical pharmacology: special safety considerations in drug development and pharmacovigilance. Drug Saf 2004; 27 (8): 535-54
11. Franconi F, Brunelleschi S, Steardo L, et al. Gender differences in drug responses. Pharmacol Res 2007 Feb; 55 (2): 81-95
12. Choquet-Kastylevsky G, Vial T, Descotes J. Allergic adverse reactions to sulfonamides. Curr Allergy Asthma Rep 2002 Jan; 2 (1): 16-25
13. Farahani P, Levine M. Pharmacovigilance in a genomic era. Pharmacogenomics J 2006 May; 6 (3): 158-61
14. Mhlongo SW, Mbokazi AJ. Ethnic differences in risks of adverse reactions: biomedical approach is insufficient to explain ethnic differences. BMJ 2006 Jun 10; 332 (7554): 1393
15. Osterborg A, Karlsson C, Lundin J, et al. Strategies in the management of alemtuzumab-related side effects. Semin Oncol 2006 Apr; 33 (2 Suppl. 5): S29-35
16. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007 Feb; 61 (2): 162-75
17. Coleman JJ, Ferner RE, Evans SJ. Monitoring for adverse drug reactions. Br J Clin Pharmacol 2006 Apr; 61 (4): 371-8
18. Statistical analysis of safety data in clinical trials: management of safety information from clinical trials. Report of CIOMS Working Group VI. Geneva: CIOMS, 2005: 131-64
19. Ferner RE, Coleman J, Pirmohamed M, et al. The quality of information on monitoring for haematological adverse drug reactions. Br J Clin Pharmacol 2005 Oct; 60 (4): 448-51
20. Seligman PJ. Thinking outside the (black) box: a new research agenda. Pharmacoepidemiol Drug Saf 2006 Jun; 15 (6): 387-9
21. Ferner RE, Aronson JK. Communicating information about drug safety. BMJ 2006 Jul 15; 333 (7559): 143-5
22. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003 Jan; 12 (1): 17-29
23. Aronson JK. A prescription for better prescribing. Br J Clin Pharmacol 2006 May; 61 (5): 487-91
24. Hallas J. Drug utilization statistics for individual-level pharmacy dispensing data. Pharmacoepidemiol Drug Saf 2005 Jul; 14 (7): 455-63
25. Berard A, Azoulay L, Koren G, et al. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007 Feb; 63 (2): 196-205
26. Stuve O, Marra CM, Cravens PD, et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 2007 Feb; 64 (2): 169-76
27. Nurse J, Edmondson-Jones P. A framework for the delivery of public health: an ecological approach. J Epidemiol Community Health 2007 Jun; 61 (6): 555-8